SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung cancers.

SCIB2 vaccine is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC). As for the SCIB1 vaccine, the synergistic potential of SCIB2 with a checkpoint inhibitor has been confirmed in preclinical tumour models and there is therefore a rationale for testing SCIB2 in combination with a PD-1 inhibitor in the clinic.